Attention those who mandate Veeva ENGAGE

So, it's dinner time here in Cali and I just listened to the earnings report recording. Consider this.

What do Prolia, Evenity, Repatha, Enbrel, Amgevita, Krypolis, Nplate, and Neulasta have in common? Two things. They are all down in Q2 and they all mandate use of Veeva ENGAGE.

Otezla meanwhile, doesn't use Veeva ENGAGE at all and sales are up 14%.

Come on TO, consider the facts. We don't care what AI has to say, there is something about what Otezla is doing that we should consider.

It seems pretty clear. We can either use the big Pharma tool of ENGAGE and continue to see our sales erode or we can actually engage customers via the platform that they most want and see sales rise.

TO, we are waiting for your leadership....

 

K

 

I cringe every time someone says Cali. Only people who aren't from California say Cali.

 

this argument is a perfect specimen of what is known as false equivalence

 

stupid rep

 

yes, just listened as well and I am a rep!! True story, hold onto your hats people......hahaha!

 

You will be in for a long wait. TO doesn't care about reps and doesn't respect them. They are waiting for you to leave.

 

You may want to look again. Repatha was up 32%.

 

Repatha was up 32% 2nd qtr. That being said no one is doing Veeva Engage to sell it. Providers aren't even answering emails anymore bc of so many reps overwhelming them that way. Look..... point is.... Pharma (especially BIG PHARMA like Amgen) just doesn't need the field sales force headcount (reps & managers & RD's) it's had in the past. Its just the way it is. Nor does it need the amount of pencil pushers and paper shufflers on staff in TO. So much waste. SMH

 

Large cuts coming end of Q3

 

Cuts to be deeper this year.

 

Total revenues up 6%. Doubtful they make cut divisions that are growing.

 

Repatha sales increased 32% year-over-year driven by 69% volume growth, offset partially by lower net selling price. Sales declined 13% quarter-over-quarter driven by unfavorable changes to estimated sales deductions. Although new-to-brand prescriptions (NBRx) in the U.S. for the proprotein convertase subtilisin/kexin type 9 (PCSK9) segment were negatively impacted by COVID-19, Repatha maintained share leadership among new patients, exiting the quarter with approximately 80% share. Repatha's year-over-year net selling price declined as a result of additional contracting to improve Medicare Part D patient access and patient affordability. We expect net selling price to be relatively stable for the remainder of the year.

 

just wait until Friday when Trump announces all the drug price cuts Good Night Irene!

 

That's only for the ditto heads who follow him on Twitter. Everyone else knows he can't do anything to drug prices, rebates or reimportation. Not a damn thing.

You sound like the special needs kind of poster who believes Trump's doctor who says viruses are from alien DNA and that cysts and tumors are from women being mean.

You know he said he hadn't asked Putin about the bounty on US Troops because he hadn't talked to him since then. Except that his own White House officials pointed out that he's had 7 conversations with Vlad since that news broke.

You and your kind are the reason we are losing this country.

 

You sound just as stupid as the people who think Trump is Jesus, but for different reasons. I bet you follow Trump on Twitter since you seem obsessed with him, and your loony conspiracy theories

 

My physicians refuse to use Veeva Engage. They tell me up front...no lunch if a platform has to be used. Many specialists say that. The few PCP will use it to feed their staff. I've had decent conversations over the phone during a lunch (virtual) that's not Veeva Engage.

 

My best interactions since this all began are over the phone or even face time where I've actually been surprised at the quality time I've gotten. I've done Engage a few times because face it, at Amgen we play the game.

So, my recipe is any interaction where I need to sell, I make a phone call.

The rest, I schedule Engage meetings with nurses and staff so that my numbers look good to TO.

TO would rather have 4 Engages a day with a bunch of staff so that they can run their analytics than 4 phone calls a day where I move product.

Think about it. It' mid morning. You are doc and you're between telemedicine visit and you have 15 minutes. Would you rather pick up the phone and have a conversation or would you rather go into your conference room and log in to some electronic platform just so you can see the "detail aid" from some big Pharma company with 20 year old data? You might even be subject to some "high gain questions" if you allow that platform. Or, you could take a call from the nimble reps who move business.

TO will always choose the platform that they can measure, not the one that moves business.

TO values what they can measure.

 

Thank you Nimble Representative.

 

TO will always choose the platform that they can measure, not the one that moves business.

Bingo....that’s most companies in this industry